基本信息 产品详情 公司简介 推荐产品
网站主页 INH14 化合物 INH14
  • 化合物 INH14|T5209|TargetMol

化合物 INH14|T5209|TargetMol

INH14
200134-22-1
220 1mg 起订
478 5mg 起订
732 10mg 起订
上海 更新日期:2024-12-12

TargetMol中国(陶术生物)

VIP3年
联系人:邵小姐
手机:4008200310 拨打
邮箱:marketing@tsbiochem.com

产品详情:

中文名称:
化合物 INH14
英文名称:
INH14
CAS号:
200134-22-1
品牌:
TargetMol
产地:
美国
保存条件:
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
纯度规格:
95.41%
产品类别:
抑制剂
货号:
T5209

Product Introduction

Bioactivity

名称INH14
描述INH14 is a novel inhibitor of the IKKα/β-dependent TLR inflammatory response (IC50s: 8.97/3.59 μM for IKKα/IKKβ).
细胞实验Human primary monocytes (8 x 10^4 cells/well) were seeded and incubated overnight with the compound, media control, or SDS (0.02%). Then, the tetrazolium salt WST-8 was added, and the cells were incubated for one additional hour at 37°C. During this period, the dehydrogenase activity of viable cells led to the production of the coloured product (formazan). The cell viability was measured with a Victor plate reader as an increase in the absorbance at 450 nm.
激酶实验IKKα and IKKβ kinase assays (ADP-GloTM 109 kinase assay) were purchased from Promega and used following the manufacturer′s instructions. The quantification of the ADP produced in the reactions (chemiluminescence) was measured with a Victor plate reader. IKKα (15 ng per reaction) or IKKβ (20 ng per reaction) were incubated with ATP (50 μM or 25 μM, respectively) and substrate-peptide (0.2 ng/ml) in the presence of vehicle or increasing concentrations of INH14 at room temperature for one hour.
动物实验8-week old, male, pathogen-free C57BL/6J mice were maintained at the animal facility (12 h light/dark cycle; standard rodent chow and water available ad libitum). For lipopeptide-induced inflammation, 5 μg/g of INH14 or vehicle were administered intraperitoneally. After one hour, P2 (2.5 μg/g) was injected and 25 μl of tail vein blood were collected at that time point (0 h) and 2 h after. The blood was centrifuged at 5 x 10^3 x g, and the supernatant frozen at -20 °C until further cytokine measurement by ELISA.
体外活性在用INH14处理的细胞中,TLR2通路部分蛋白质的过表达显示目标位于复合体TAK1/TAB1下游。INH14减少了由脂肽(TLR2配体)激活的细胞中IkBα的降解。通过激酶实验确认,INH14的靶点是激酶IKKα和/或IKKβ(IC50 IKKα=8.97μM; IC50 IKKβ=3.59μM)。
体内活性体内实验显示,INH14减少了脂肽诱导炎症后形成的TNFα,治疗卵巢癌细胞时,INH14降低了NF-kB的固有活性,并减少了这些细胞的伤口愈合能力。
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度DMSO : 100 mg/mL (416.14 mM)
关键字inhibit | IKK | IκB kinase | INH 14 | I kappa B kinase | INH-14 | INH14 | Inhibitor
相关产品GSK8612 | BX795 | Rosmarinic acid | Amlexanox | Malachite green oxalate | Resveratrol | ACHP Hydrochloride | BAY 11-7082 | SC-514 | Allicin | CCCP | JTP 0819958 - HOIPIN-1
相关库抑制剂库 | 抗癌活性化合物库 | 经典已知活性库 | 抗癌化合物库 | 已知活性化合物库 | 激酶抑制剂库 | 抗衰老化合物库 | NO PAINS 化合物库 | 抗卵巢癌化合物库 | NF-κB 通路分子库
INH14|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及多种类型的生化试剂产品,包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等,此外,我们还建设有CADD(计算机辅助药物设计)研究中心、药理实验室、药化合成平台三大技术中心,全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持,我们将有效帮助您缩短研发周期,取得更成功的结果。

成立日期 (12年)
注册资本 566.265100万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

化合物 INH14相关厂家报价

内容声明
拨打电话 立即询价